MacroGenics stock: MGC026 data support new combination study

MacroGenics reported positive interim Phase 1 results for its MGC026 antibody-drug conjugate on October 23, 2026. In its press release, the company said the data showed durable activity across multiple solid tumor types and supported further development in front-line recurrent or metastatic squamous cell carcinoma of the head and neck, or SCCHN.

MGC026 shows activity in early testing

The update covered data from a September 1, 2026 cutoff. Among 17 response-evaluable patients in dose escalation who received at least 6 milligrams per kilogram, the confirmed objective response rate was 29 percent and the disease control rate was 65 percent. The median duration of response was 10.2 months.

In the SCCHN expansion cohort, 22 patients were evaluable for response. The best overall response rate was 27 percent, including four confirmed and two unconfirmed partial responses, while the disease control rate was 64 percent. MacroGenics said the patients had been heavily pretreated, with a median of three prior systemic treatment lines.

Safety profile and next study

Across the full safety population of 85 treated patients, Grade 3 or higher treatment-related adverse events occurred in 51 percent. Treatment-related events led to discontinuation in 5 percent of patients, and no Grade 5 treatment-related events were reported. In the SCCHN cohort, no treatment-related discontinuations, interstitial lung disease, pneumonitis or ocular toxicity were observed.

Enrollment is continuing in Stage 2 of the Phase 1 study, with updated data expected in mid-2027. MacroGenics plans to initiate an expansion cohort in early 2027 that will evaluate MGC026 with pembrolizumab in front-line patients with PD-L1-positive recurrent or metastatic SCCHN.

MacroGenics stock and investor context

Lang & Schwarz quoted MacroGenics at 2.12 euros on October 29, 2026, at 22:59:30 Berlin time. Investors should distinguish the company-reported clinical findings from the market valuation: the interim data remain early-stage results and do not establish regulatory approval or commercial success. The real-time quote of MacroGenics stock is available separately.

The broader U.S. equity backdrop can be followed through the S&P 500 market overview.

More news and analyses on MacroGenics stock are available in the company topic area.